Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$26.33 USD

26.33
304,606

+0.83 (3.25%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $26.36 +0.03 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Pacira BioSciences, Inc. [PCRX]

Reports for Purchase

Showing records 681 - 700 ( 717 total )

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 681

08/24/2012

Daily Note

Pages: 5

EMA Concerns Regarding DepoCyte Manufacturing Not Material, In Our View

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 682

08/22/2012

Daily Note

Pages: 5

July Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $18 Fair Value

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 683

08/17/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 684

08/09/2012

Company Report

Pages: 8

Q2 EXPAREL Sales Beat as Launch Off to Very Promising Start; Reiterate OUTPERFORM and $18 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 685

08/06/2012

Industry Report

Pages: 17

August and Remaining 2012 Catalysts for Emerging Pharmaceuticals.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 686

07/25/2012

Daily Note

Pages: 5

June Wolters Kluwer Data for EXPAREL. Reiterate OUTPERFORM and $18 Fair Value.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 687

07/20/2012

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 688

06/20/2012

Company Report

Pages: 8

May Wolters Kluwer Data for EXPAREL Suggests Solid Second Month of Sales

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 689

06/06/2012

Daily Note

Pages: 5

New Health Economics Data Provides Compelling Marketing Tool for Exparel, In Our View

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 690

06/03/2012

Industry Report

Pages: 19

Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 691

05/23/2012

Daily Note

Pages: 5

April Wolters Kluwer Data for EXPAREL; Reiterate OUTPERFORM and $15 Fair Value

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 692

05/09/2012

Company Report

Pages: 8

Q1 Financials: We Believe April EXPAREL Sales Suggest Solid Start to Launch. Reiterate OUTPERFORM and $15 FV.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 693

04/23/2012

Company Report

Pages: 8

We Estimate Financing Extends Cash Runway Into Potential Profitability - Reiterate OUTPERFORM, FV Lowered to $15

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 694

04/09/2012

Company Report

Pages: 8

EXPAREL Now Commercially Available-We Believe Groundwork Laid for a Successful aunch-Reiterate

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 695

03/30/2012

Industry Report

Pages: 20

Emerging Pharmaceuticals -Q2 2012 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 696

03/30/2012

Industry Report

Pages: 5

LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of April 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 697

03/27/2012

Company Report

Pages: 8

Q4 Financials Uneventful. We See a Robust EXPAREL Launch the Week of April 9. Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 698

01/22/2012

Industry Report

Pages: 25

Ue with Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 699

01/09/2012

Company Report

Pages: 8

3-Month Delay in EXPAREL Launch Results in Only Slight Revenue Impact But Provides Additional Time for Manufacturing and Pre-Launch Activities.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 700

01/06/2012

Industry Report

Pages: 37

LIFE SCIENCES: 2012 Life Sciences and Healthcare Preview: Macro and Sector Trends; Catalysts; Top Picks

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 75.00

Research Provided by a Third Party